194 related articles for article (PubMed ID: 1764367)
1. Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.
Pezzoni G; Grandi M; Biasoli G; Capolongo L; Ballinari D; Giuliani FC; Barbieri B; Pastori A; Pesenti E; Mongelli N
Br J Cancer; 1991 Dec; 64(6):1047-50. PubMed ID: 1764367
[TBL] [Abstract][Full Text] [Related]
2. Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.
Geroni C; Pesenti E; Tagliabue G; Ballinari D; Mongelli N; Broggini M; Erba E; D'Incalci M; Spreafico F; Grandi M
Int J Cancer; 1993 Jan; 53(2):308-14. PubMed ID: 8425770
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic and antitumor activity of MEN 10710, a novel alkylating derivative of distamycin.
Bigioni M; Salvatore C; Palma C; Manzini S; Animati F; Lombardi P; Pratesi G; Supino R; Zunino F
Anticancer Drugs; 1997 Oct; 8(9):845-52. PubMed ID: 9402311
[TBL] [Abstract][Full Text] [Related]
4. In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
Ripamonti M; Pezzoni G; Pesenti E; Pastori A; Farao M; Bargiotti A; Suarato A; Spreafico F; Grandi M
Br J Cancer; 1992 May; 65(5):703-7. PubMed ID: 1586598
[TBL] [Abstract][Full Text] [Related]
5. The effects of a benzoic acid mustard derivative of distamycin A (FCE 24517) and related minor groove-binding distamycin analogues on the activity of major groove-binding alkylating agents.
Coley HM; Mongelli N; D'Incalci M
Biochem Pharmacol; 1993 Feb; 45(3):619-26. PubMed ID: 8442762
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517).
Capolongo L; Melegaro G; Broggini M; Mongelli N; Grandi M
Br J Cancer; 1993 Nov; 68(5):916-9. PubMed ID: 8105866
[TBL] [Abstract][Full Text] [Related]
7. FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis.
Sola F; Farao M; Ciomei M; Pastori A; Mongelli N; Grandi M
Invasion Metastasis; 1995; 15(5-6):222-31. PubMed ID: 8765197
[TBL] [Abstract][Full Text] [Related]
8. Selective DNA interaction of the novel distamycin derivative FCE 24517.
Broggini M; Erba E; Ponti M; Ballinari D; Geroni C; Spreafico F; D'Incalci M
Cancer Res; 1991 Jan; 51(1):199-204. PubMed ID: 1859575
[TBL] [Abstract][Full Text] [Related]
9. Decreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine).
Ciomei M; Pastori W; Capolongo L; Geroni C; Melegaro G; Pennella G; Grandi M
Br J Cancer; 1995 Dec; 72(6):1504-8. PubMed ID: 8519667
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A.
Baraldi PG; Romagnoli R; Beria I; Cozzi P; Geroni C; Mongelli N; Bianchi N; Mischiati C; Gambari R
J Med Chem; 2000 Jul; 43(14):2675-84. PubMed ID: 10893305
[TBL] [Abstract][Full Text] [Related]
11. Distamycin-A derivatives potentiate tumor-necrosis-factor activity via the modulation of tyrosine phosphorylation.
Zou JP; Nathan I; Dvilansky A; Parola AH; Zamai M; Kafka M
Int J Cancer; 1997 Sep; 72(5):810-4. PubMed ID: 9311598
[TBL] [Abstract][Full Text] [Related]
12. PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met ethoxy HCl, a new chemotherapeutic agent active against drug-resistant tumor cell lines.
Yagi MJ; Chin SE; Scanlon KJ; Holland JF; Bekesi JG
Biochem Pharmacol; 1985 Jul; 34(13):2347-54. PubMed ID: 4040366
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the toxicity of distamycin derivatives on cancer cell lines and rat heart.
Agen C; Sironi AM; Danesi R; Costa M; Bernardini N; Paparelli A; Della Torre P; Del Tacca M
Toxicology; 1992 Nov; 75(3):209-19. PubMed ID: 1455430
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of FCE 26644 a new growth-factor complexing molecule.
Sola F; Farao M; Pesenti E; Marsiglio A; Mongelli N; Grandi M
Cancer Chemother Pharmacol; 1995; 36(3):217-22. PubMed ID: 7781141
[TBL] [Abstract][Full Text] [Related]
16. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow.
Fiebig HH; Berger DP; Köpping K; Ottenheijm HC; Zylicz Z
J Cancer Res Clin Oncol; 1990; 116(6):550-6. PubMed ID: 2254373
[TBL] [Abstract][Full Text] [Related]
18. The unique interaction with immunity of FCE 24517, an antitumor drug with a novel mode of action.
Riganti F; Sironi M; Kankova M; D'Incalci M; Spreafico F; Mantovani A; Vecchi A
Int J Immunopharmacol; 1992 Feb; 14(2):239-51. PubMed ID: 1624224
[TBL] [Abstract][Full Text] [Related]
19. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
Struck RF; Dykes DJ; Corbett TH; Suling WJ; Trader MW
Br J Cancer; 1983 Jan; 47(1):15-26. PubMed ID: 6821629
[TBL] [Abstract][Full Text] [Related]
20. Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent.
Hickman JA; Stevens MF; Gibson NW; Langdon SP; Fizames C; Lavelle F; Atassi G; Lunt E; Tilson RM
Cancer Res; 1985 Jul; 45(7):3008-13. PubMed ID: 4005840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
